1. Home
  2. CELC

CELC

Celcuity Inc.

Logo Celcuity Inc.

Health Care

Medical Specialities

Nasdaq

as 04-17-2024 1:51pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Founded: 2011 Country:
United States
United States
Employees: N/A City: MINNEAPOLIS
Market Cap: 557.6M IPO Year: 2017
Target Price: $29.00 AVG Volume (30 days): 213.2K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.69 EPS Growth: N/A
52 Week Low/High: $8.39 - $22.19 Next Earning Date: 05-13-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 131.34%

Share on Social Networks: